Edition:
United Kingdom

Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

16.90USD
16 Nov 2018
Change (% chg)

$0.70 (+4.32%)
Prev Close
$16.20
Open
$16.10
Day's High
$16.92
Day's Low
$16.05
Volume
109,079
Avg. Vol
101,582
52-wk High
$19.55
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

Codexis Q2 Loss Per Share $0.07
Wednesday, 8 Aug 2018 

Codexis Inc ::CODEXIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.02.Q2 LOSS PER SHARE $0.07.Q2 REVENUE $13.5 MILLION VERSUS I/B/E/S VIEW $11.6 MILLION.SEES FY 2018 REVENUE $60 MILLION TO $63 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.PHASE 1A CLINICAL TRIAL FOR CDX-6114 INITIATED.SEES FY PRODUCT REVENUE TO BE $25 MILLION TO $28 MILLION.  Full Article

Codexis Announces Proposed Public Offering Of Common Stock
Thursday, 5 Apr 2018 

April 6 (Reuters) - Codexis Inc ::CODEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Telemark Asset Management LLC reports 6.72 pct passive stake in Codexis ‍​as of Nov 10
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Codexis Inc :Telemark Asset Management LLC reports 6.72 percent passive stake in Codexis Inc ‍​as of November 10 - SEC Filing.  Full Article

Codexis Q3 non-gaap loss per share $0.17
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Codexis Inc ::Codexis reports financial results for the third quarter of 2017.Q3 non-gaap loss per share $0.17.Q3 loss per share $0.21.Sees FY 2017 revenue $50 million to $53 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Codexis Inc - ‍total revenues for Q3 of 2017 were $10.0 million compared with $14.9 million for q3 of 2016​.Codexis Inc - ‍gross margin on product sales is expected to be between 40% and 43% for 2017​.  Full Article

Codexis Inc, Nestlé Health Science enter strategic collaboration​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Codexis Inc :Codexis Inc - ‍co, Nestlé Health Science enter strategic collaboration​.Codexis Inc - ‍Codexis receives an upfront payment of $14 million and potential milestones and royalties depending on product success for deal​.Codexis Inc - deal ‍includes an option for global development of CDX-6114 for PKU​.Codexis Inc - ‍Codexis will be responsible for clinical development costs for CDX-6114 up to and including Phase 1 in healthy volunteers​.Codexis - after ‍phase 1, Nestlé health science will have option to obtain exclusive global license to CDX-6114.Codexis - after ‍Phase 1, Nestlé health science will be responsible for all future development and commercialization of CDX-6114​.  Full Article

Codexis files for mixed shelf of up to $80 million
Friday, 9 Dec 2016 

Codexis Inc :Files for mixed shelf of up to $80 million - sec filing.  Full Article